Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Gains from Investment Securities (2016 - 2025)

Lipocine (LPCN) has disclosed Gains from Investment Securities for 11 consecutive years, with $5870.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities fell 97.95% year-over-year to $5870.0, compared with a TTM value of $5639.0 through Sep 2025, down 98.03%, and an annual FY2024 reading of $10209.0, down 96.11% over the prior year.
  • Gains from Investment Securities was $5870.0 for Q3 2025 at Lipocine, down from $349616.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $4.0 million in Q3 2022 and bottomed at -$506408.0 in Q3 2021.
  • Average Gains from Investment Securities over 5 years is $304998.7, with a median of $8039.5 recorded in 2024.
  • The sharpest move saw Gains from Investment Securities skyrocketed 513228.95% in 2021, then plummeted 125.32% in 2022.
  • Year by year, Gains from Investment Securities stood at $488192.0 in 2021, then plummeted by 107.01% to -$34243.0 in 2022, then skyrocketed by 98.74% to -$431.0 in 2023, then soared by 2468.68% to $10209.0 in 2024, then crashed by 42.5% to $5870.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for LPCN at $5870.0 in Q3 2025, $349616.0 in Q1 2025, and $10209.0 in Q4 2024.